Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of
doses, when combined with cytarabine, in the treatment of patients with primary refractory or
relapsed acute myeloid leukemia (AML).